drugset / Trial / NCT04739293

Study of ON 123300 in Patients With Advanced Cancer

NCT04739293

Phase 1 Unknown 36 enrolled Traws Pharma, Inc.
NaSequentialOpen-labelTreatment

Summary

This study will investigate the safety of the drug ON 123300 at increasing doses to determine the best dose to use in future clinical trials.

Timeline

Start
2021-05-13
Primary completion
2024-10
Completion
2024-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Narazaciclib Small molecule 40 mg Oral
Subject Narazaciclib Small molecule 80 mg Oral
Subject Narazaciclib Small molecule 120 mg Oral

Indications

No indication recorded.